Medically reviewed by Casey Gallagher, MD Acral peeling skin syndrome is a rare genetic condition mainly causing skin to peel on the extremities—usually, the feet and hands but also the arms and legs.

Quoin Initiates Peeling Skin Syndrome Clinical Program Further Expansion of International Reach for Netherton Syndrome Clinical Trials Significant Insider Share Purchases by the Entire Management ...

Quoin Pharmaceuticals Ltd. announced promising results from its ongoing clinical study of QRX003 for pediatric Peeling Skin Syndrome, demonstrating significant improvements in skin appearance ...

ASHBURN, Va., Aug. 06, 2024 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”) a clinical stage, specialty ...

There is currently no approved treatment or cure for peeling skin syndrome and there are no clinical studies listed on clinicaltrials.gov as actively recruiting and dosing subjects, thus ...

The firm continues to progress QRX003 through late-stage clinical trials targeting Netherton Syndrome, another uncommon skin condition. Peeling Skin Syndrome is a rare genetic disorder that ...

Quoin Pharmaceuticals Ltd. has filed a U.S. patent application for new topical formulations aimed at treating several skin diseases, specifically Netherton Syndrome (NS) and Peeling Skin Syndrome.

Stevens-Johnson Syndrome is a rare and life-threatening genetic condition that causes the skin to peel off. When a woman in Ofakim was diagnosed, doctors at Soroka were able to save her.

Quoin CEO Dr. Michael Myers said, “The third quarter has been marked by notable achievements, including expanding the clinical reach of our lead product QRX003 into Peeling Skin Syndrome.